Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
Collaboration leverages Absci’s leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications
VANCOUVER, Wash. and BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ABSI), a data-first generative AI drug creation company, and , a pioneer in protein-based therapeutics for animal health, today announced a strategic partnership to harness Absci’s AI Drug Creation models to create an innovative Half-Life Extension (HLE) platform for animal health applications.
“Absci has built a leading generative AI Drug Creation platform for therapeutic antibodies and we’re excited to bring this expertise into animal health,” said Sean McClain, Founder and CEO of Absci. “We look forward to working with Invetx to address the large underserved animal health market by leveraging our proven success in designing Half-Life Extension technologies for human antibodies to advance the standard of care in veterinary medicine.”
Under the terms of the agreement, Absci will utilize its AI models to design novel modular antibody sequences that confer Half-Life Extension in specific animal species, Invetx will have rights, subject to the agreement’s financial and other terms, to use the HLE platform in multiple products to enhance duration of therapeutic effect and customer convenience, both significant potential differentiators in the animal health market. The partnership includes R&D funding, as well as election fees, milestone payments, and royalties on a per-product basis.
“Invetx is a pioneer in creating novel, protein-based animal health therapeutics and we are excited to leverage the power of AI to enhance the development of our pipeline", said Juergen Horn, President of Invetx. “We selected Absci for this collaboration because of their leading platform for generative AI design of human antibodies. By partnering together, we have an opportunity to build a scalable platform for bringing innovative specialty therapeutics for companion animals to market.”
The collaboration has the potential to address significant unmet needs in animal health, with initial applications for large-market indications in canines, and with the potential to expand to other companion animals.
About Absci
is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our ™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit and follow us on LinkedIn (), X (Twitter) (), and .
About Invetx
Invetx is a pioneer in creating novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. The company leverages a best-in-class, fully integrated biotechnology platform for the discovery, development, and manufacturing of veterinary monoclonal antibodies, and is developing a diverse product pipeline addressing chronic and severe diseases in companion animals. Invetx was acquired by Dechra Pharmaceuticals Limited, a global specialist veterinary pharmaceuticals business, in July 2024. Invetx is headquartered in Boston, Massachusetts. For more information, see .
Absci Forward-Looking Statements
Certain statements in this press release that are not historical facts are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “may,” “pursues,” “anticipates,” “plans,” “believes,” “aims,” “potential,” “forecast,” “estimates,” “extends,” “expects,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding the capabilities of our Integrated Drug Creation platform, our technology development efforts and the application of those efforts, the potential benefits of our partnership with Invetx, the plans and success of our current and future partnerships and the ability to generate advancements towards treating disease using generative AI drug creation to accelerate the development of novel candidate therapies, the anticipated value to us under our partnerships, and our internal therapeutic asset programs, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to our ability to effectively collaborate on research, drug discovery and development activities with our partners or potential partners, our dependence on third parties to support our internal development programs, including for the manufacture and supply of preclinical and clinical supplies of our product candidates or components thereof, our existing and potential partners’ ability and willingness to pursue the development and commercialization of programs or product candidates under the terms of our partnership agreements, and overall market conditions and regulatory developments that may affect our and our partners’ activities under these agreements, along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Absci Investor Contact
Alex Khan
VP, Finance & Investor Relations
Absci Media Contact
Invetx Media Contact
Jonny Armstrong
Global Corporate Communications Director
